Skip to main content
Research and Innovation logo
Receive our editor’s picks: 

Coronavirus outbreak

24 June 2021

How we prepare for an ‘age of pandemics’

The current pandemic caught the world off guard but there are more to come, and we need to work out how to better prepare for and respond to future crises before they occur, an audience at the European Commission’s annual Research and Innovation Days conference has heard.
21 June 2021

Covid-19 hastened the digital shift with consequences for the ‘data divide’, wellbeing

Sometimes it can seem like we’ve uploaded our whole lives to the internet: bank accounts, social media posts, dating profiles, work emails – it’s all out there in that nebulous cloud of digital information that is the world wide web. The problems with this new digital way of life are well known. Social media is thought to produce echo chambers in which people aren’t exposed to healthy debates. Big tech companies make money from our personal data. Workers in the gig economy are paid a pittance to deliver groceries to the better off.
07 June 2021

How vulnerable groups were left behind in pandemic response

Viruses like Covid-19 make no distinction between those they infect. They should in theory cause disease in the rich just as they do the poor and pay no heed to social status or cultural background. But in practice the pandemic has widened the gulf between vulnerable groups and other populations in Europe rather than helping to level out inequalities in society, researchers warn.
05 May 2021

Five things to know about: Mixing and matching coronavirus vaccines

Amid global vaccine rollouts, with nearly 1.2 billion doses currently administered, some countries have recommended a mixed-dose approach where a first prime shot is followed by a booster of a second type. 
08 April 2021

Q&A: BioNTech vaccine is only ‘mRNA 1.0’. This is just the beginning, say co-founders

The successful development of mRNA vaccines for Covid-19 is ‘transformational’ and opens the doors to new types of vaccines for other infectious diseases as well as cancer, according to Dr Özlem Türeci and Dr Uğur Şahin, the co-founders of Germany’s BioNTech.
07 April 2021

How a year of coronavirus activity unfolded at the EU's medicines regulator

The speed with which coronavirus vaccines have been developed surprised everyone and could transform public health into the future, says Dr Fergus Sweeney, head of the clinical studies and manufacturing taskforce at the European Medicines Agency (EMA). Here he gives us a glimpse at the work of the regulator over the past year as part of the fight against Covid-19.
29 March 2021

Covid-19 variants: Five things to know about how coronavirus is evolving

The Sars-CoV-2 virus is changing in ways that are making it more transmissible, increasing the severity of disease it causes and allowing it to infect people who should have immunity. These variants are causing concern among global health experts, particularly as there are signs that some vaccines may be less effective against them. 
25 March 2021

The new antibody that may be able to stay ‘one step ahead’ of coronavirus mutations

A new antibody that can mount a double attack on the Sars-CoV-2 virus by binding to two different sites on the spike protein is starting human trials, leading to hopes of an antibody therapy that can maintain its effectiveness even against new variants of coronavirus.
04 March 2021

‘Needle in a haystack’: The hunt for coronavirus drug compounds in a Belgian biosafety lab

Professor Johan Neyts, a virologist at the Rega Institute for Medical Research at KU Leuven in Belgium, leads a team searching for drugs that can help us in the fight against Covid-19. His laboratory is part of two projects that are screening millions of compounds to find some that block the coronavirus from replicating and so keep patients from falling sick. He told Horizon about why this search is so important and how it might keep us safe from future pandemics.
18 February 2021

How a trial that mirrors intensive care practices is pinpointing life-saving coronavirus treatments

Two anti-inflammatory drugs – tocilizumab and sarilumab – as well as steroids, have been identified as potential life-saving coronavirus treatments thanks to a trial set up in the wake of the 2009 swine flu pandemic that mirrors the way that people receive multiple treatments while in intensive care.